Skip to content

Tag: Glucocorticoid receptor

Explore our medication guides and pharmacology articles within this category.

How does fluticasone mechanism of action target inflammation?

3 min read
According to StatPearls, fluticasone exerts its potent anti-inflammatory effects by having a direct local effect at the site of administration. Understanding **how does fluticasone mechanism of action** work is key to appreciating its effectiveness as a topical corticosteroid used in the management of allergic rhinitis, asthma, and other inflammatory respiratory conditions.

Understanding What Is the Mechanism of Action of Flunisolide?

4 min read
As a potent synthetic corticosteroid hundreds of times more potent than hydrocortisone, the mechanism of action of Flunisolide centers on its powerful anti-inflammatory and immunosuppressive effects. It works by modulating cellular activity at the genetic level to manage chronic inflammatory conditions such as asthma and allergic rhinitis.

What is the mechanism of action of corticosteroids in the eye?

5 min read
Since the 1950s, ophthalmic steroids have been a cornerstone of treating eye inflammation, utilizing a complex anti-inflammatory process. So, **what is the mechanism of action of corticosteroids in the eye?** These drugs inhibit the inflammatory cascade at a molecular and genetic level by binding to specific receptors within ocular cells.

Understanding How Does Desonide Work for Inflammatory Skin Conditions

3 min read
As a low-potency topical corticosteroid, desonide is a common treatment for a variety of inflammatory skin conditions, including eczema and psoriasis. This medication's ability to soothe irritated skin stems from a sophisticated anti-inflammatory action at the cellular level, targeting the very mechanisms that cause redness, swelling, and itching. By understanding exactly **how does desonide work**, patients and healthcare providers can appreciate its targeted therapeutic benefits.

What type of drug is vamorolone? A Look at Dissociative Steroids

4 min read
In October 2023, the U.S. Food and Drug Administration (FDA) approved vamorolone (brand name Agamree) for the treatment of Duchenne muscular dystrophy (DMD), signaling a new approach in steroid therapy. This first-in-class drug is a novel dissociative corticosteroid, designed to retain the therapeutic benefits of traditional steroids while minimizing common adverse side effects.